From Hysteria to DSM: The Historical and Clinical Evolution of PMS as a Mental Health Diagnosis

The classification of premenstrual syndrome (PMS) and its severe variant, premenstrual dysphoric disorder (PMDD), as mental health issues represents a complex interplay between medical science, cultural narratives, and diagnostic evolution. The journey from the 19th-century concept of "female hysteria" to the current inclusion of PMDD in the Diagnostic and Statistical Manual of Mental Disorders (DSM) illustrates how the medical community has grappled with defining the boundary between physical and psychological symptoms. This evolution is not merely a timeline of dates but a reflection of shifting paradigms regarding women's health, hormonal influences, and the validity of psychiatric diagnoses.

The identification of PMS as a mental health issue did not happen in isolation; it was deeply influenced by historical biases, research methodologies, and the specific criteria used to define the disorder. Early descriptions of menstrual-related symptoms often leaned heavily toward psychological interpretations, sometimes overshadowing the significant physical manifestations of the condition. As the field progressed, the focus shifted toward establishing PMDD as a distinct diagnostic entity, recognized by major health organizations like the World Health Organization (WHO) and the American Psychiatric Association (APA).

This transformation involved rigorous attempts to validate the disorder through clinical descriptions, laboratory studies, and family history analysis. However, the path to this recognition was fraught with challenges, including contradictory findings, confirmation bias in research, and the historical tendency to "psychologize" women's health issues. The current understanding of PMDD acknowledges it as a condition with both biological underpinnings and significant psychological impact, requiring a nuanced approach to diagnosis and treatment.

Historical Roots: From Hysteria to Modern Psychologizing

The conceptualization of menstrual-related symptoms as primarily psychological has deep historical roots that extend back to the 19th century. During this era, the medical community often attributed women's health complaints to "female hysteria," a diagnosis that was heavily influenced by the myth of the irrational female. This historical context is critical to understanding why PMS research has often been typified by contradictory and contested findings. The emphasis on mood-based symptoms, rather than a holistic view of the menstrual cycle, created a legacy of "psychologizing" PMS, where the condition was framed as a disorder of the mind rather than a complex interaction of hormonal and somatic factors.

Katharina Dalton, a prominent figure in this field, attempted to counter the undue emphasis on mood-based symptoms, yet she also inadvertently contributed to a dangerous legal precedent. Dalton and Holton (2000) noted the "hijacking of PMS by psychologists," a critique that highlights the tension between medical and psychological interpretations. Unfortunately, this dynamic also led to the use of PMS as a mitigation defense in legal cases, such as murder charges, based on the premise that the crime was committed "under the influence of PMS." This legal application further cemented the view of PMS as a mental health issue, albeit one that was often unscientific and potentially harmful.

The transition from these historical biases to modern diagnostic criteria was gradual. For over thirty years, clinical descriptions of PMS remained predominantly psychological in focus. This shift was solidified when the American Psychiatric Association (APA) included premenstrual disorders in the DSM. The inclusion of "Late Luteal Phase Dysphoric Disorder" (LLPDD) in the DSM-III-R in 1987 marked a pivotal moment. This was later replaced by "Premenstrual Dysphoric Disorder" (PMDD) in the DSM-IV in 1994. These inclusions signaled a formal recognition of the condition as a mental health disorder, distinct from general PMS, which was often viewed as a less severe form of the same issue.

However, this classification has been subject to significant criticism. Critics argue that by focusing on mood-based symptoms, research has overlooked critical physical elements, such as period pain, which is known to affect mood and fatigue. The "psychologizing" of PMS has led to a form of confirmation bias, where studies select participants based on mood criteria, thereby ignoring the broader spectrum of menstrual cycle-related symptoms. This bias is evident in the tools used for assessment, such as the Daily Record of Severity of Problems (DRSP) and the Moos Menstrual Distress Questionnaire (MDQ), which over-emphasize emotional and behavioral symptoms.

Diagnostic Evolution: The DSM and ICD Classifications

The formal recognition of PMDD as an independent diagnostic entity represents a major milestone in the history of women's mental health. This recognition was achieved through the collaboration of the American Psychiatric Association (APA) and the World Health Organization (WHO). The DSM-5-TR (Text Revision) provides a detailed diagnostic framework that distinguishes PMDD from mild, non-pathological mood changes that many women experience.

According to the DSM-5-TR, PMDD is diagnosed when a patient exhibits at least five specific symptoms during the luteal phase of the menstrual cycle. These symptoms must include at least one of the following core affective symptoms: affective lability (mood swings), irritability, depressed mood, or anxiety. Additional symptoms may include loss of interest, fatigue, feeling emotionally overwhelmed, and physical symptoms. Crucially, these symptoms must follow a cyclical pattern, occurring in most cycles over the past year, appearing a week before menstruation, and resolving within a few days after the onset of flow.

The diagnostic criteria also emphasize the requirement for significant distress and functional impairment. The symptoms must interfere with work, school, or social activities, distinguishing PMDD from the milder, transient mood changes that are considered a normal part of the menstrual cycle for many women. This distinction is vital for clinical practice, as it prevents the over-diagnosis of a disorder for symptoms that are within the normal range of human experience.

The World Health Organization (WHO) has also played a critical role in legitimizing this diagnosis. In the International Statistical Classification of Diseases and Related Health Problems, Eleventh Revision (ICD-11), PMDD is assigned the code GA34.41. It is classified under "diseases of the genitourinary system," reflecting its biological and hormonal origins. However, it is also cross-listed under depressive disorders due to the prominence of mood symptomatology. This dual classification underscores the complex nature of the disorder, which bridges the gap between gynecological and psychiatric domains.

The following table compares the diagnostic criteria and classification of PMDD across major medical systems:

The development of these criteria was not without controversy. The inclusion of PMDD in the DSM was met with skepticism regarding its biological validity. Critics argued that the diagnosis was influenced by a "sympathetic reaction" to the challenges faced by modern, high-functioning women, rather than a clear biological basis. Despite this, the consensus among major health organizations is that PMDD is a valid, treatable condition that requires specific clinical attention.

The Research Bias: Mood vs. Physical Symptoms

A critical issue in the identification of PMS as a mental health issue is the methodological bias present in decades of research. Systematic reviews, considered the gold standard for evidence-based management, have historically relied on clinical trials that selected participants based predominantly on mood-based criteria. This approach has led to a skewed understanding of the disorder, where the physical manifestations of the menstrual cycle are often neglected.

The most widely used clinical tools for recording daily symptoms, such as the Daily Record of Severity of Problems (DRSP) and the Moos Menstrual Distress Questionnaire (MDQ), are designed to capture emotional and behavioral symptoms. Consequently, a vast majority of clinical trials have evaluated only a small subset of PMS patients, focusing almost exclusively on psychological distress. This creates a circular logic: if the tools only measure mood, the resulting data will only show mood symptoms, reinforcing the idea that PMS is primarily a mental health issue.

This bias has significant implications for the understanding of the disorder's etiology. Period pain, for instance, is by far the most common menstrual cycle-related symptom, yet it is frequently excluded from diagnostic criteria for PMS. Research indicates that period pain has a direct effect on premenstrual mood, fatigue, and other symptoms. By ignoring these physical components, the medical community has missed critical elements in the cause and treatment of menstrual cycle-related symptoms.

The impact of this bias is evident in the difficulty clinicians face when identifying menstrual cycle-related symptoms. If PMS is understood as essentially mood-based, clinicians may struggle to recognize the full spectrum of the disorder. This limitation is further compounded by the fact that many studies have not confirmed the phases of the menstrual cycle in research participants, making it unclear if worsening symptoms truly occur during the luteal phase or are merely retrospective recollections.

The reliance on retrospective self-reports is particularly problematic. Research has mostly asked women to recall past experiences of symptom worsening, which is prone to memory bias. Prospective daily ratings, as recommended by the DSM-5-TR, are necessary to accurately capture the cyclical nature of the symptoms. The Structured Clinical Interview for DSM-IV-TR PMDD (SCID-PMDD) was developed to address this, utilizing five scales for self-monitoring over at least two menstrual cycles. However, the historical dominance of mood-based criteria has left a gap in the understanding of the somatic aspects of the disorder.

Biological Validity and Neurodevelopmental Factors

Despite the historical focus on psychological symptoms, recent evidence suggests that PMDD has deep biological underpinnings. The disorder is increasingly understood as having neurodevelopmental origins, potentially linked to conditions such as attention deficit hyperactivity disorder (ADHD) and adverse childhood experiences. These factors may affect the fronto-limbic circuit, which is responsible for regulating emotions.

The biological validity of PMDD remains a subject of debate, but there is growing consensus that affected individuals exhibit increased sensitivity to gonadal hormonal fluctuations. This sensitivity is observed not only during the premenstrual phase but also during pregnancy and the perimenopausal phases of life. The hormonal fluctuations associated with the menstrual cycle appear to trigger or exacerbate symptoms in susceptible individuals.

The concept of Premenstrual Exacerbation (PME) further highlights the interaction between the menstrual cycle and pre-existing mental health conditions. PME refers to the worsening of psychiatric symptoms, such as depression, mania, and psychosis, in the week or two before menstruation. While PME has been understudied compared to other cycle-related illnesses, it underscores the link between hormonal changes and mental health.

The following table outlines the potential biological mechanisms and risk factors associated with PMDD:

The recognition of these biological factors challenges the purely psychological interpretation of PMS. It suggests that the disorder is not merely a "mental health issue" in the sense of a primary psychiatric condition, but rather a complex interplay of hormonal, neurological, and psychological factors. This shift in understanding is crucial for developing effective treatments that address the root causes rather than just the symptoms.

Clinical Management and Treatment Protocols

The identification of PMDD as a mental health issue has led to the development of specific treatment protocols. The disorder is considered treatable, with a range of therapeutic options available. Selective Serotonin Reuptake Inhibitors (SSRIs) have been shown to treat both the psychiatric and physical symptoms of PMDD. Commonly prescribed SSRIs include sertraline, paroxetine, fluoxetine, and escitalopram.

In addition to SSRIs, other medications have demonstrated benefit. Quetiapine can be used as an adjunct to an SSRI, while oral contraceptives and calcium supplementation have also shown efficacy in managing symptoms. The choice of treatment often depends on the specific symptom profile of the patient and the severity of the disorder.

The clinical management of PMDD requires a careful assessment of the patient's symptoms over time. The use of prospective daily ratings is essential to confirm the cyclical nature of the symptoms and rule out other mental health disorders. The Structured Clinical Interview for DSM-IV-TR PMDD (SCID-PMDD) serves as a diagnostic tool, utilizing five scales for self-monitoring over at least two menstrual cycles. This rigorous approach ensures that the diagnosis is accurate and that the treatment is targeted effectively.

The following table summarizes the primary treatment options for PMDD:

It is important to note that while PMDD is classified as a mental health disorder, its treatment often involves a multidisciplinary approach. The integration of gynecological and psychiatric care is essential for managing the complex symptoms of the disorder. The recognition of PMDD as an independent diagnostic entity has facilitated this integration, allowing for more comprehensive care for affected women.

The Impact of Psychologizing and Cultural Bias

The history of PMS as a mental health issue is inextricably linked to cultural biases and the tendency to "psychologize" women's health. The myth of the "irrational female" has persisted through the centuries, influencing how menstrual symptoms are perceived and treated. This bias has led to a situation where the physical aspects of the menstrual cycle are often overlooked in favor of psychological interpretations.

The impact of this bias is evident in the research landscape. As noted, the majority of clinical trials have selected participants based on mood-based criteria, leading to a skewed understanding of the disorder. This has resulted in a form of confirmation bias, where the research confirms what it expects to find, reinforcing the idea that PMS is primarily a mental health issue.

The "hijacking of PMS by psychologists" is a phrase that captures the tension between the medical and psychological communities. While the APA and WHO have recognized PMDD as a valid diagnosis, the underlying biological mechanisms remain somewhat inexplicit. This has led to criticism that the diagnosis is a product of a "sympathetic reaction" to the challenges faced by modern women, rather than a clear biological entity.

Despite these criticisms, the recognition of PMDD has provided a necessary framework for understanding and treating the disorder. It has legitimized the distress and socio-occupational impairment experienced by affected women, offering a pathway to effective care. However, the field continues to grapple with the balance between acknowledging the psychological symptoms and recognizing the underlying biological and physical causes.

Conclusion

The identification of PMS as a mental health issue is a complex historical and clinical narrative. From the 19th-century concept of "female hysteria" to the modern classification of PMDD in the DSM and ICD, the journey has been marked by a tension between psychological and biological interpretations. The inclusion of PMDD as an independent diagnostic entity has provided a crucial framework for understanding and treating the disorder, yet challenges remain regarding the biological validity and the potential for research bias.

The evolution of this diagnosis reflects a broader shift in the medical community's understanding of women's health. The recognition of PMDD as a distinct condition has allowed for targeted treatments, including SSRIs, hormonal therapies, and nutritional supplements. However, the field must continue to address the historical bias of "psychologizing" PMS, ensuring that both the physical and psychological aspects of the menstrual cycle are fully integrated into clinical practice.

The future of PMDD research lies in bridging the gap between gynecology and psychiatry. By acknowledging the neurodevelopmental underpinnings and hormonal sensitivities, clinicians can provide more holistic care for women experiencing premenstrual symptoms. The continued refinement of diagnostic criteria and treatment protocols will be essential in managing this complex disorder, ensuring that the distress and impairment associated with PMDD are effectively addressed.

Sources

1. https://www.ncbi.nlm.nih.gov/books/NBK565629/
2. https://www.frontiersin.org/journals/global-womens-health/articles/10.3389/fgwh.2023.1181583/full
3. https://www.psychiatry.org/news-room/apa-blogs/the-menstrual-cycle-and-mental-health-concerns